IL2 and melanoma: Among melanoma patients in the PROCLAIM registry who were treated with HD IL-2 after prior treatment with ipilimumab or an anti-PD1 antibody, the response rates were 21% (11 of 52 patients) and 22.5% (9 of 40 patients), respectively (3, 4).